- Home
- WNEB vs STTK Comparison
WNEB vs STTK Comparison
Compare WNEB & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WNEB
- STTK
- Stock Information
- Founded
- WNEB 1853
- STTK 2016
- Country
- WNEB United States
- STTK United States
- Employees
- WNEB N/A
- STTK N/A
- Industry
- WNEB Savings Institutions
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- WNEB Finance
- STTK Health Care
- Exchange
- WNEB Nasdaq
- STTK Nasdaq
- Market Cap
- WNEB 195.7M
- STTK 37.6M
- IPO Year
- WNEB N/A
- STTK 2020
- Fundamental
- Price
- WNEB $9.97
- STTK $0.83
- Analyst Decision
- WNEB Buy
- STTK Hold
- Analyst Count
- WNEB 3
- STTK 4
- Target Price
- WNEB $9.75
- STTK $3.00
- AVG Volume (30 Days)
- WNEB 210.4K
- STTK 401.8K
- Earning Date
- WNEB 07-22-2025
- STTK 07-31-2025
- Dividend Yield
- WNEB 2.81%
- STTK N/A
- EPS Growth
- WNEB N/A
- STTK N/A
- EPS
- WNEB 0.53
- STTK N/A
- Revenue
- WNEB $72,966,000.00
- STTK $4,606,000.00
- Revenue This Year
- WNEB N/A
- STTK N/A
- Revenue Next Year
- WNEB $7.94
- STTK N/A
- P/E Ratio
- WNEB $18.80
- STTK N/A
- Revenue Growth
- WNEB N/A
- STTK 69.65
- 52 Week Low
- WNEB $6.64
- STTK $0.69
- 52 Week High
- WNEB $10.08
- STTK $4.99
- Technical
- Relative Strength Index (RSI)
- WNEB 65.44
- STTK 39.19
- Support Level
- WNEB $9.28
- STTK $0.77
- Resistance Level
- WNEB $10.04
- STTK $0.91
- Average True Range (ATR)
- WNEB 0.29
- STTK 0.08
- MACD
- WNEB 0.11
- STTK -0.02
- Stochastic Oscillator
- WNEB 95.36
- STTK 16.23
About WNEB Western New England Bancorp Inc.
Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the company's revenues, profits, and assets are derived by the Bank from banking products and services.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.